Core Technology Platforms

D-Crypt Platform

One of Premas Biotech's flagship innovations is the D-Crypt platform, a proprietary yeast-based (Saccharomyces cerevisiae) expression system engineered to produce difficult-to-express proteins. Many therapeutically relevant proteins, such as G-protein-coupled receptors (GPCRs), ion channels, transporters, and multi-pass membrane proteins, are notoriously hard to express in functional form using traditional bacterial, mammalian, or standard yeast systems. The D-Crypt platform is designed to overcome these bottlenecks, enabling the production of correctly folded, functional proteins at improved yields.

This platform is particularly valuable for structural biology, antibody discovery against membrane targets, and the development of therapeutics that depend on complex protein targets.

Triple Antigen and Virus-Like Particle (VLP) Technology

Premas Biotech has developed capabilities in the production of virus-like particles and multi-antigen vaccine constructs. The company gained notable attention for its work on a triple-antigen virus-like particle vaccine candidate for COVID-19, developed using its proprietary yeast expression platform. This approach aimed to present multiple viral antigens simultaneously to elicit a broad immune response, demonstrating the versatility of the company's expression technology for vaccine applications.

Products and Services

Recombinant Protein Expression Services

Premas Biotech offers end-to-end recombinant protein production services, including:

• Expression of difficult-to-express and complex proteins using the D-Crypt platform
• Multi-host expression capabilities spanning bacterial, yeast, and mammalian systems
• Codon optimization and gene synthesis support
• Cell line development and clone selection
• Fermentation and process development from small scale to pilot scale
• Protein purification and analytical characterization

Drug Discovery Services

The company provides integrated drug discovery support to pharmaceutical and biotech partners, encompassing:

• Target identification and validation
• Assay development and screening
• Hit-to-lead and lead optimization support
• Antibody discovery, including work against challenging membrane protein targets
• Structural biology support enabled by functional protein production

Biologics and Biosimilars Development

Premas Biotech supports the development of biologic drugs and biosimilars, offering process development and analytical services that help clients advance candidates toward clinical and commercial stages. Its expertise in complex protein production is applied to monoclonal antibodies, fusion proteins, and other biologic modalities.

Vaccine Development

Leveraging its VLP and multi-antigen expression capabilities, the company engages in vaccine research and development. Its yeast-based production system offers advantages in scalability and cost-effectiveness, which are important considerations for global vaccine access.

Analytical and Characterization Services

Supporting its core offerings, Premas Biotech provides analytical services for protein characterization, quality assessment, and structural analysis, which are essential for both research applications and regulatory-grade development work.

Collaborations and Partnerships

Premas Biotech has pursued strategic collaborations with international partners to advance its technology and expand its reach. Notably, the company has worked with Oravax Medical, a joint venture involving Premas and other partners, focused on developing oral vaccine candidates using the company's VLP technology. Such partnerships reflect the company's strategy of licensing and co-developing its platform technologies with global players in the pharmaceutical and vaccine sectors.

The company also serves as a contract research and development organization, working with academic institutions, biotech startups, and established pharmaceutical companies that require specialized protein production and discovery capabilities.

Areas of Application

The work performed by Premas Biotech spans a wide range of therapeutic and research areas, including:

• Infectious disease and vaccine development
• Oncology and immuno-oncology research
• Membrane protein-targeted therapeutics
• Structural biology and drug target studies
• Diagnostics and research reagent supply

Distinguishing Characteristics

What sets Premas Biotech apart in the biotechnology landscape is its focus on solving hard technical problems in protein expression rather than competing purely on commoditized services. The D-Crypt platform represents a differentiated technological asset that addresses a genuine gap in the industry—the reliable production of complex proteins that are essential for modern drug discovery but difficult to make using conventional methods.

The company blends a services-based business model with a technology-licensing and co-development approach, allowing it to generate value both from client engagements and from the intellectual property it develops around its proprietary platforms. This dual approach positions Premas Biotech as both a service provider and an innovation partner.

Summary

Premas Biotech is a specialized Indian biotechnology company operating in the recombinant protein, drug discovery, and biologics development space. Through its proprietary D-Crypt yeast expression platform and its virus-like particle technology, the company tackles some of the most challenging problems in protein science, supporting applications ranging from vaccine development to antibody discovery against difficult targets. By combining contract research and development services with proprietary technology platforms and strategic partnerships, Premas Biotech contributes to the global effort to bring complex biologics and vaccines from concept to reality.